US 12,390,484 B2
Adenosine derivative and pharmaceutical composition comprising the same
Lianhong Xu, Palo Alto, CA (US)
Assigned to Brii Biosciences, Inc., Durham, NC (US)
Filed by Brii Biosciences, Inc., Durham, NC (US)
Filed on Sep. 15, 2023, as Appl. No. 18/467,985.
Application 18/467,985 is a continuation of application No. 17/583,805, filed on Jan. 25, 2022, granted, now 11,793,827.
Claims priority of provisional application 63/141,450, filed on Jan. 25, 2021.
Prior Publication US 2024/0245716 A1, Jul. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 19/16 (2006.01); A61K 31/4439 (2006.01); A61K 31/4985 (2006.01); A61K 31/7076 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/7076 (2013.01) [A61K 31/4439 (2013.01); A61K 31/4985 (2013.01); A61K 47/10 (2013.01); C07H 19/16 (2013.01)] 19 Claims
 
1. An adenosine derivative having a structure of formula (I) or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein:
A and E are each independently selected from the group consisting of a bond, —(CO)—, —(CO)-G-, —(CO)-G-(C1-10alkylene)-J-, —(CO)-G-(C2-10alkenylene)-J-, and —(CO)-G-(C2-10alkynylene)-J-; wherein:
G is selected form the group consisting of a bond, O, NH, and S;
J is selected form the group consisting of a bond, O, NH, S, —(CO)-G-;
R1 is

OG Complex Work Unit Chemistry
 wherein R4 is H, C1-5alkyl, C1-5haloalkyl, or C1-5alkoxy;
R2 is selected from the group consisting of H, C1-20alkyl, C1-20haloalkyl, C1-20alkoxy, C2-20alkenyl, C2-20alkynyl, C3-20cycloalkyl, 3- to 20-membered heterocycloalkyl, aryl, and heteroaryl; and
R3 is selected from the group consisting of H, —(CO)-G-C1-10alkyl, C1-10alkyl, C1-10haloalkyl, C2-10alkenyl, C2-10alkynyl, C3-12cycloalkyl, 3- to 12-membered heterocycloalkyl, aryl, and heteroaryl.